Wall Street is positive on Alnylam Pharmaceuticals, Inc. (ALNY). On average, analysts give Alnylam Pharmaceuticals, Inc. a Strong Buy rating. The average price target is $166.55, which means analysts expect the stock to add by 23.06% over the next twelve months.
That average ranking earns Alnylam Pharmaceuticals, Inc. an Analyst Rating of 60, which is better than 60% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Alnylam Pharmaceuticals, Inc. Stock Today?
Alnylam Pharmaceuticals, Inc. (ALNY) stock is up 1.5% while the S&P 500 is unchanged 0% as of 11:35 AM on Friday, Sep 25. ALNY is higher by $2.00 from the previous closing price of $133.34 on volume of 235,317 shares. Over the past year the S&P 500 is up 9.03% while ALNY is higher by 69.05%. ALNY lost -$7.57 per share the over the last 12 months.
Click Here to get the full report on Alnylam Pharmaceuticals, Inc. (ALNY) Stock.
